Heinrich Michael C
Division of Hematology and Medical Oncology, Oregon Health & Science University Cancer Institute; and Portland VA Medical Center, Portland, OR 97201, USA.
Mini Rev Med Chem. 2004 Mar;4(3):255-71. doi: 10.2174/1389557043487394.
Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.
FLT3受体酪氨酸激酶的激活突变是急性髓性白血病（AML）中最常见的复发性基因异常。小分子抑制剂抑制FLT3激酶活性已被提议作为AML的一种新型治疗方法。本文将对候选FLT3抑制剂的临床前和临床开发进行综述。
